The latest induced, embryonic, and other pluripotent stem cell news.
AMSBIO has introduced its GMP-grade StemFit® for Differentiation, a medium designed for the differentiation of human induced pluripotent stem (hiPS) and embryonic stem (hES) cells. This formulation, now compliant with Good Manufacturing...
In a recent policy position statement, GlaxoSmithKline (GSK) mentioned that stem cell technology has its use cases in drug discovery, albeit it needs to be done in an ethical, safe way. Here's...
Cellino announced it has launched what they report as the world's first hospital-based autologous induced pluripotent stem cell (iPSC) plant at Mass General Brigham’s Gene and Cell Therapy Institute (GCTI). They are...
Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing...
Japan is reportedly in the final stages of approving the first induced pluripotent stem cell (iPS cell) treatment for inclusion in its national healthcare system. Approval would position Japan among the first...